Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Unaudited Financial Results (Standalone And Consolidated) For The Third Quarter And Nine Months Ended December 31, 2021

 Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2021. The said meeting of the Board commenced at 5.30 p.m. and concluded at 10.15 p.m. The copy of the said results together with Press Release, Management Discussion & Analysis, Investor Presentation and Limited Review Report of the Auditors is enclosed herewith.
11-02-2022

Glenmark Pharma share price rises 2% on launch of nasal spray for COVID-19 patients

 The nitric oxide nasal spray, to be sold under the brand name FabiSpray, is for treating adult patients with COVID-19 who have a high risk of progression of the disease, the company has said
09-02-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Glenmark launches Nitric Oxide Nasal Spray (FabiSpray(r)) in India for the Treatment of Adult Patients with COVID-19 in partnership with SaNOtize
09-02-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Enclosed please find herewith the details of Earnings Call slated for Monday, February 14, 2022 at 8:30 a.m. - 9:30 a.m. (1ST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.
03-02-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Closure of Trading Window

 We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, February 11, 2022, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2021. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from December 31, 2021 to February 13, 2022 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2021.
02-02-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Board Meeting Intimation for Board Meeting Intimation For Unaudited Financial Results Of The Company For The Third Quarter And Nine Months Ended December 31, 2021

 GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2022 ,inter alia, to consider and approve We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, February 11, 2022, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2021. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from December 31, 2021 to February 13, 2022 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2021
02-02-2022

Glenmark gets nod from US Food & Drug Administration for generic drug

 Glenmark Pharmaceuticals on Friday said its US-based unit has received approval from the US health regulator to market Metronidazole Vaginal gel, in the American market. The drug firm has received final approval by the United States Food & Drug Administration (USFDA) for its product which is a generic version of Bausch Health US LLC's MetroGel-Vaginal, the drug firm said in a statement. According to IQVIA sales data for the 12-month period ending November 2021, the MetroGel-Vaginal Gel achieved annual sales of approximately around USD 60.4 million. Glenmark's current portfolio consists of 173 products authorised for distribution in the US marketplace and 46 ANDA's pending approval with the USFDA. In addition to these internal filings, the drug firm continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, Glenmark noted.
28-01-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Glenmark Pharmaceuticals receives ANDA approval for Metronidazole Vaginal Gel, 0.75%
28-01-2022

Glenmark Pharma arm gets final USFDA approval for blood pressure drug

 The approval granted to Glenmark Pharmaceuticals Inc, USA by the United States Food Drug Administration (USFDA) is for Bisoprolol Fumarate and Hydrochlorothiazide tablets of strengths 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 MG, the company said in a statement.
27-01-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Glenmark Pharmaceuticals receives ANDA approval for Bisoprolol Fumarate and Hydrochlorothiazide Tablets USP, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg
27-01-2022
Next Page
Close

Let's Open Free Demat Account